Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genetics Institute Inc.

(GENIZ)

Oppenheimer & Co. analyst Matthew Geller repeated a "market perform" rating on the Cambridge, Mass., company following the announcement of Phase II results showing that

Neumega

Interleukin-11 was effective in restoring platelets following chemotherapy (see Clinical

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE